

Table 12.6i
Immunosuppression Use for Antirejection Treatment from Transplant
to One Year Following Transplantation, 1997 to 2006
Recipients with Lung Transplants

	Year of Transplant									
	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
Transplants	948	893	922	977	1,083	1,054	1,099	1,185	1,407	1,406
Tx with Antirejection Treatments	421	403	396	432	500	425	357	384	435	387
Antibodies										
Any in Category	11.6%	15.9%	16.4%	18.8%	11.2%	13.4%	16.2%	13.8%	12.4%	12.9%
Atgam/NRATG/NRATS	7.8%	10.9%	8.3%	7.4%	4.2%	3.1%	4.8%	4.2%	4.1%	7.0%
OKT3	4.3%	3.2%	3.0%	2.5%	1.4%	1.9%	0.8%	1.0%	0.9%	0.3%
Thymoglobulin	0.0%	0.7%	5.1%	5.8%	5.8%	4.9%	5.6%	6.8%	6.7%	5.4%
Zenapax	0.2%	2.2%	1.0%	3.0%	0.8%	5.2%	7.0%	1.8%	0.5%	0.0%
Simulect	0.0%	0.2%	0.8%	2.8%	0.6%	0.2%	0.6%	0.5%	1.1%	0.3%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.5%	0.8%	0.5%	0.5%	0.0%
Corticosteroids										
Any in Category	94.1%	91.6%	93.2%	88.2%	92.6%	95.1%	96.1%	93.8%	94.9%	91.2%
Steroids	94.1%	91.6%	93.2%	88.2%	92.6%	95.1%	96.1%	93.8%	94.9%	91.2%
Antimetabolites										
Any in Category	1.9%	0.7%	1.5%	1.2%	1.2%	0.2%	1.4%	0.5%	1.1%	1.3%
Cytosan	0.5%	0.2%	0.8%	0.5%	0.2%	0.2%	0.6%	0.5%	0.5%	1.3%
Methotrexate	1.4%	0.5%	1.5%	0.7%	1.0%	0.0%	0.8%	0.0%	0.7%	0.0%

Source: OPTN/SRTR Data as of May 1, 2008.

Notes:

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.